ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly & Co. will acquire Hypnion, a small Lexington, Mass., neuroscience-based drug company focused on sleep disorders. Steven M. Paul, a Lilly executive vice president, says the purchase "provides Lilly with a broader and more substantive presence in the area of sleep disorder research." Hypnion announced in January that its small-molecule insomnia compound HY10275 had good results in a Phase II clinical trial. Lilly is developing its own insomnia treatment, pruvanserin.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X